ASTRAZENECA PLC Reports Fourth Quarter FY 2022 Earnings Results on February 9, 2023.

Earnings Overview

ASTRAZENECA ($LSE:AZN): AstraZeneca PLC reported its fourth quarter fiscal year 2022 results on February 9, 2023, which ended on December 31, 2022. Total revenue for the quarter was USD 901.0 million, a 359.7% increase compared to the same period the previous year. Unfortunately, net income decreased 6.7% to USD 11207.0 million.

Price History

This surge came after the announcement of the Q4 earnings, which were reported to be better than expected. Investors were pleased with the company’s financial performance in the previous quarter, leading to a surge in their stock prices. Furthermore, investors were encouraged by the company’s long-term outlook, which promised further growth and success in the future. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Astrazeneca Plc. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Astrazeneca Plc. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Astrazeneca Plc. More…

Key Ratios Snapshot

Some of the financial key ratios for Astrazeneca Plc are shown below. More…

Analysis

GoodWhale has conducted an extensive analysis of ASTRAZENECA PLC‘s performance in terms of financial and business aspects. After our assessment, we have concluded that this company is a medium-risk investment. The findings of our analysis show that there are two risk warnings present in their income statement and balance sheet. We encourage you to become a registered user so you can check out the details of our analysis. To ensure the most accurate data and to keep your investments safe, it is essential that you gain access to our comprehensive assessments before making any decisions about your investments. In addition, GoodWhale provides a range of other resources to help improve your understanding of ASTRAZENECA PLC’s performance and its associated risks. Our team of experts are available to help you with any questions you may have regarding our analysis or other related topics. More…

Peers

AstraZeneca PLC is a pharmaceutical company that specializes in the development, manufacture, and marketing of prescription drugs. The company has a diversified product portfolio, which includes medications for cardiovascular, gastrointestinal, and respiratory diseases, as well as cancer. AstraZeneca PLC competes with Sanofi SA, Merck & Co Inc, and Pfizer Inc in the global pharmaceutical market.

– Sanofi SA ($OTCPK:SNYNF)

As of 2022, Sanofi SA has a market cap of 100.1B and a Return on Equity of 7.56%. The company is a French multinational pharmaceutical company headquartered in Paris, France, and is one of the world’s largest pharmaceutical companies. Sanofi is a diversified company, focused on human health. It covers seven areas: diabetes solutions, rare diseases, multiple sclerosis, oncology, immunology, vaccines and consumer healthcare.

– Merck & Co Inc ($NYSE:MRK)

Merck & Co Inc is a pharmaceutical company with a market cap of 236.25B as of 2022. The company has a return on equity of 28.84%. The company produces a variety of drugs and vaccines for human and animal health.

– Pfizer Inc ($NYSE:PFE)

Pfizer Inc is a research-based pharmaceutical company with a market cap of 241.95B as of 2022. The company has a return on equity of 24.63%. Pfizer’s main focus is on the discovery, development, and commercialization of innovative therapeutics to treat patients with serious diseases. The company has a portfolio of products in various therapeutic areas, including cardiovascular, inflammation, immunology, oncology, pain, and rare diseases.

Summary

Investing in AstraZeneca PLC (AZN) is currently looking more attractive following its strong fourth quarter performance in fiscal year 2022. Total revenue for the quarter increased by 359.7% compared to the same period the year before, despite net income decreasing slightly by 6.7%. This news has had a positive effect on AZN’s stock price, and with revenue growth in this quarter, astute investors may want to consider adding AZN to their portfolios. AZN is a unique stock given its strong performance potentially making it a good long-term investment opportunity.